会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明申请
    • Hydrogel bioscaffoldings and biomedical device coatings
    • 水凝胶生物支架和生物医学装置涂料
    • US20090226519A1
    • 2009-09-10
    • US11110223
    • 2005-04-19
    • Charles ClaudeConnie KwokGene MichalJihong QuSophia Liao
    • Charles ClaudeConnie KwokGene MichalJihong QuSophia Liao
    • A61K9/14A61K35/12A61K38/16A61P9/00
    • A61L27/3834A61L27/26A61L27/3826A61L27/383A61L27/3873A61L27/52C08L89/06C08L5/08
    • Bioscaffoldings formed of hydrogels that are crosslinked in situ in an infarcted region of the heart (myocardium) by a Michael's addition reaction or by a disulfide bond formed by an oxidative process are described. Each of the bioscaffoldings described includes hyaluronan as one of the hydrogel components and the other component is selected from collagen, collagen-laminin, poly-1-lysine, and fibrin. The bioscaffolding may further include an alginate component. The bioscaffoldings may have biofunctional groups such as angiogenic factors and stem cell homing factors bound to the collagen, collagen-laminin, poly-1-lysine, or fibrinogen hydrogel component. In particular, the biofunctional groups may be PR11, PR39, VEGF, bFGF, a polyarginine/DNA plasmid complex, or a DNA/polyethyleneimine (PEI) complex. Additionally, the hydrogel components may be injected into the infarct region along with stem cells and microspheres containing stem cell homing factors. The bioscaffolding may be formed on a stent or a cardiac medical device.
    • 描述了由水凝胶形成的生物支架,其通过迈克尔加成反应或通过氧化过程形成的二硫键在心脏(心肌)的梗死区域原位交联。 所描述的每个生物支架包括透明质酸作为水凝胶组分之一,另一组分选自胶原,胶原 - 层粘连蛋白,聚-1-赖氨酸和纤维蛋白。 生物支架还可包括藻酸盐组分。 生物支架可具有诸如血管生成因子和与胶原,胶原 - 层粘连蛋白,聚-1-赖氨酸或纤维蛋白原水凝胶组分结合的干细胞归巢因子的生物功能组。 特别地,生物功能组可以是PR11,PR39,VEGF,bFGF,聚精氨酸/ DNA质粒复合物或DNA /聚乙烯亚胺(PEI)复合物。 此外,水凝胶组分可以与含有干细胞归巢因子的干细胞和微球一起注入梗塞区域。 生物支架可以形成在支架或心脏医疗装置上。
    • 5. 发明授权
    • Hydrogel bioscaffoldings and biomedical device coatings
    • 水凝胶生物支架和生物医学装置涂料
    • US08828433B2
    • 2014-09-09
    • US11110223
    • 2005-04-19
    • Charles ClaudeConnie KwokGene MichalJihong QuSophia Liao
    • Charles ClaudeConnie KwokGene MichalJihong QuSophia Liao
    • A61K9/14
    • A61L27/3834A61L27/26A61L27/3826A61L27/383A61L27/3873A61L27/52C08L89/06C08L5/08
    • Bioscaffoldings formed of hydrogels that are crosslinked in situ in an infarcted region of the heart (myocardium) by a Michael's addition reaction or by a disulfide bond formed by an oxidative process are described. Each of the bioscaffoldings described includes hyaluronan as one of the hydrogel components and the other component is selected from collagen, collagen-laminin, poly-1-lysine, and fibrin. The bioscaffolding may further include an alginate component. The bioscaffoldings may have biofunctional groups such as angiogenic factors and stem cell homing factors bound to the collagen, collagen-laminin, poly-1-lysine, or fibrinogen hydrogel component. In particular, the biofunctional groups may be PR11, PR39, VEGF, bFGF, a polyarginine/DNA plasmid complex, or a DNA/polyethyleneimine (PEI) complex. Additionally, the hydrogel components may be injected into the infarct region along with stem cells and microspheres containing stem cell homing factors. The bioscaffolding may be formed on a stent or a cardiac medical device.
    • 描述了由水凝胶形成的生物支架,其通过迈克尔加成反应或通过氧化过程形成的二硫键在心脏(心肌)的梗死区域原位交联。 所描述的每个生物支架包括透明质酸作为水凝胶组分之一,另一组分选自胶原,胶原 - 层粘连蛋白,聚-1-赖氨酸和纤维蛋白。 生物支架还可包括藻酸盐组分。 生物支架可具有诸如血管生成因子和与胶原,胶原 - 层粘连蛋白,聚-1-赖氨酸或纤维蛋白原水凝胶组分结合的干细胞归巢因子的生物功能组。 特别地,生物功能组可以是PR11,PR39,VEGF,bFGF,聚精氨酸/ DNA质粒复合物或DNA /聚乙烯亚胺(PEI)复合物。 此外,水凝胶组分可以与含有干细胞归巢因子的干细胞和微球一起注入梗塞区域。 生物支架可以形成在支架或心脏医疗装置上。
    • 7. 发明申请
    • Method of delivering parathyroid hormone to a human
    • 甲状旁腺激素给人的方法
    • US20060127320A1
    • 2006-06-15
    • US11347551
    • 2006-02-03
    • Henry CostantinoConnie Kwok
    • Henry CostantinoConnie Kwok
    • A61L9/04A61M11/00A61K38/29
    • A61K9/0043A61K31/724A61K38/29A61K47/40A61M15/08
    • What is described is a method of delivering PTH to a human, comprising exposing a layer of mucosal cells to a mixture of PTH and an enhancer, wherein the enhancer is capable of modulating the barrier function of a cellular tight junction. Specifically, the method of delivering PTH to a human by intranasal administration comprises use of an aqueous solution of growth and excipients in a bottle and a droplet-generating actuator attached to the bottle and fluidly connected to the PTH solution in the container, wherein the actuator produces a spray of the PTH solution through a tip of the actuator when the actuator is engaged, wherein the spray of PTH solution has a spray pattern ellipticity ratio of from about 1.0 to about 1.4 when measured at a height of 3.0 cm from the actuator tip.
    • 所描述的是将PTH递送到人的方法,包括将粘膜细胞层暴露于PTH和增强子的混合物,其中增强剂能够调节细胞紧密连接的屏障功能。 具体地说,通过鼻内给药将PTH递送给人的方法包括使用瓶中的生长和赋形剂的水溶液和附着在瓶子上的液滴产生致动器并且流体连接到容器中的PTH溶液,其中致动器 当致动器接合时,通过致动器的尖端产生PTH溶液的喷雾,其中在距离致动器尖端3.0cm的高度处测量时,PTH溶液的喷雾具有约1.0至约1.4的喷雾图案椭圆率 。